SpIntellx, the leader in Spatial Biology leveraging Explainable AI for predicting the progression of disease, announced today its rebranding as PredxBio. The PredxBio platform is designed to empower drug discovery, translation, and clinical trials, initially focusing on immuno-oncology space.
PITTSBURGH, April 4, 2023 /PRNewswire-PRWeb/ -- SpIntellx, the leader in Spatial Biology leveraging Explainable AI for predicting the progression of disease, announced today its rebranding as PredxBio (pronounced, "pre-dix-bio"). The PredxBio platform is designed to empower drug discovery, translation, and clinical trials, initially focusing on immuno-oncology space.
Oncology is the world's largest and fastest growing therapeutic area and immunotherapies have emerged as a promising option for late-stage cancer patients over the last decade. Immune cells play a pivotal role in detecting and destroying abnormal cells, but cancer cells can sometimes completely evade or even suppress the immune response. A deeper and enhanced understanding of the spatial and temporal heterogeneity in the tumor microenvironment (TME) is needed to establish effective immunotherapy treatments. PredxBio is leading the way to deliver transformative insights into the heterogeneous TME for cancer patients, harnessing the latest advances in Spatial Biology and Explainable AI (xAI) to predict highly accurate responses to therapies.
"We are taking this critical step in our evolution as a Spatial Biology based company to reflect the exciting capabilities we have developed leveraging unbiased spatial analytics and xAI to accelerate biomarker discovery, identify novel drug targets, and design better clinical trials identifying sub-populations of response with significantly greater precision. There is a critical need to lower costs and shorten the time it takes to develop cancer drugs for pharmaceutical companies, and we believe that the new PredxBio platform is uniquely poised to address these critical challenges head-on," said B. Dusty Majumdar, CEO of PredxBio.
The new PredxBio platform seamlessly integrates multimodal data including spatial proteomics, spatial transcriptomics and brightfield pathology to unravel the hidden circuitries of tumor microenvironment and reveal the complex network biology of cancer. The PredxBio platform performs highly scalable, xAI powered unbiased spatial analyses of multiplex immunofluorescent, mass cytometry, and transmitted light images to enable the generation of actionable insights for accelerating biomarker discovery, identifying novel drug targets and designing better clinical trials to stratify patients cohorts.By delving into organizing principles of spatial intratumor heterogeneity and the spatial relationships between different proteins/nucleotides, PredxBio is able to quantify cell-cell interactions, identify intermediate cell types and states, and automatically discover microdomains, which are repeated spatial arrangements or clusters of diverse cells within the tissue environments. Microdomains are critical to gaining a mechanistic understanding of tumor initiation, tumor progression, and response to therapy.
The PredxBio platform is designed to improve prediction accuracies and drive personalized therapeutic options for selecting optimal therapeutics based on insights into spatial tumor biology of individual patients and their potential outcomes. With the launch of the PredxBio brand, we are positioning the company in Spatial Biology with the truly unique capability of unraveling the hidden biological circuitries of cancer to predict patient outcomes with 90%+ accuracy.
About PredxBio
PredxBio is a Pittsburgh, PA-based scaling-stage company focused on the development of explainable AI-powered spatial analytics software platforms to decipher the complex cancer biology and bend the survival curve for immunotherapy cancer patients. PredxBio's solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. PredxBio has already completed engagements with early paying customers including pharma partners who are harnessing PredxBio's solutions to assess treatment response in immunotherapy.
http://www.predxbio.com
Media Contact
S. Chakra Chennubhotla, PredxBio, Inc., 1 4122123115, [email protected]
SOURCE PredxBio, Inc.
Share this article